Major publications

1: Facchinetti F, Hollebecque A, Bahleda R, Loriot Y, Olaussen KA, Massard C, Friboulet L. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. Clin Cancer Res. 2019 Oct 4. doi: 10.1158/1078-0432.CCR-19-2035. [Epub ahead of print] Review. PubMed PMID: 31585937.

Genetic tumor adaptation to kinase inhibitors

This group belongs to the UMR 981 - Molecular predictors and new targets in oncology

The research groups of Gustave Roussy are gathered in 12 research units:

UMR 1279 - Tumor cell dynamics

UMR 1287 - Hematopoietic stem cells and the development of myeloid malignancies

At the apex of the hematopoietic tissue, hematopoietic stem cells (HSCs) self-renew and give rise to all blood cell lineages. The tightly regulated mechanisms involved in normal hematopoiesis include a number of intrinsic factors, such as transcription factors & epigenetic marks, and extrinsic factors such as surrounding cells of the niche and the cytokines they produce.

UMR 9018 - Metabolic and systemic aspects of oncogenesis for new therapeutic approaches (METSY)

Head of unit: Dr Catherine Brenner

UMR 9019 - Genome Integrity and Cancers

The Genome Integrity and Cancers unit focuses its efforts on understanding the molecular and cellular mechanisms that govern the stability of the genome, one of the major areas of research at the Gustave Roussy Institute.

Etude ONCOVID

Covid-19 - Epidémiologie du SARS-CoV-2 et mortalité par maladie de Covid-19 chez les patients français porteurs d’un cancer et traités par l'hydroxychloroquine et l'azithromycine.

Synthèse d'actualités scientifiques liées au COVID-19, réalisée par des experts de Gustave Roussy.